As of November 6, 2026, Harvard Bioscience Inc. is a publicly traded company (Nasdaq: HBIO). The largest holder reporting an active stake on Schedule 13D is William Snider, a director, at 15.97%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Leviticus Partners LP (5.2%) (Schedule 13D, March 23, 2026).
Is this your company?
About to sign with, pay or invest in Harvard Bioscience Inc.? See the free Snapshot first.
Free to see. No signup.
Is Harvard Bioscience Inc. a real, registered company?
- Harvard Bioscience Inc files with the SEC under CIK 1123494 (its SEC filings).
- Its shares are listed under the ticker HBIO on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Holliston, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under HARVARD BIOSCIENCE INC in our court records and SEC 8-K records (as of 2026-11-06).
- Layoffs: 1 exit or restructuring plan reported on Form 8-K, Item 2.05 (latest filed 2026-01-29).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Leviticus Partners LP (filed 2026-09-22).
Who are Harvard Bioscience Inc.'s owners and officers?
Harvard Bioscience Inc.: incorporated in Delaware; business address in Holliston, Massachusetts; industry Laboratory Analytical Instruments (Schedule 13G/A, 2026-09-22).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-09-22 | Leviticus Partners LP | 5.2% |
| Schedule 13G/A, 2026-05-14 | Leviticus Partners LP | 6.5% |
| Schedule 13D, 2026-03-23 | William Snider | 15.97% |
| Schedule 13G/A, 2026-02-12 | Leviticus Partners LP | 7.6% |
| Schedule 13G/A, 2025-11-03 | Leviticus Partners LP | 7.5% |
| Schedule 13G/A, 2025-08-07 | Leviticus Partners LP | 9.2% |
| Schedule 13G/A, 2025-07-17 | Blackrock, Inc. | 2.5% |
Questions about who owns Harvard Bioscience Inc.
Who owns Harvard Bioscience Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Harvard Bioscience Inc.: William Snider (15.97%, Schedule 13D, filed 2026-03-23) and Leviticus Partners LP (5.2%, Schedule 13G/A, filed 2026-09-22).
Who are the largest shareholders of Harvard Bioscience Inc.?
By the share each holder's latest filing reports, the largest holders of Harvard Bioscience Inc. on this page are William Snider (15.97%) and Leviticus Partners LP (5.2%).
When did William Snider buy into Harvard Bioscience Inc.?
The filings give report dates, not purchase dates. The earliest filing from William Snider on this page is the Schedule 13D, filed 2026-03-23, reporting 15.97%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Harvard Bioscience Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Harvard Bioscience Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Harvard Bioscience Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Harvard Bioscience Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 2,452,566 shares (53.9% of shares outstanding) (Form 4, 2025-08-19).
- , the chief executive and a director: 180,000 shares (4.0% of shares outstanding) (Form 4, 2026-03-23).
- , the chief financial officer: 159,019 shares (3.5% of shares outstanding) (Form 4, 2025-03-21).
- , a director: 58,669 shares (1.3% of shares outstanding) (Form 4, 2026-06-12).
- , a director: 48,556 shares (1.1% of shares outstanding) (Form 4, 2026-06-11).
Shares outstanding: 4,552,305 as of 2026-08-04, from the company's latest SEC cover page.
How much has Harvard Bioscience Inc. raised?
No fundraising or offering filing from Harvard Bioscience Inc. is on file with us.
Red flags found
1 exit or restructuring plan on Form 8-K (latest Form 8-K, 2026-01-29).
Keep reading
More on Harvard Bioscience Inc. and the records around it.
Harvard Bioscience Inc. elsewhere on the record
- 5%+ stake filings Sep 2026
- Layoff notices Jan 2026
Companies that share a holder
- Leviticus Partners LP also filed stake reports on 6 other companies: Maris Tech Ltd. (Sep 2026), SEQUANS COMMUNICATIONS (May 2026), UNIVERSAL ELECTRONICS INC (May 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/harvard-bioscience